Invenshure Announces GeneMatters acquisition As Part Of A $60Million Series C Financing Of Genome Medical

Financing Led by Casdin Capital with Participation from Leading Life Sciences Investors.

Invenshure announced that GeneMatters has been acquired by Genome Medical, the leading nationwide genomic care delivery company.  Founded by Invenshure and Jill Davies, a genetic counselor and thought leader in the field, GeneMatters is a Minneapolis-based company providing telehealth genetic counseling and software solutions that increase access to genetic services.

Recommended AI News: HashCash to Render Utility Coin Offering to Singapore-Based Startup

Invenshure previously announced an investment into GeneMatters by Casdin Capital in November of 2020 and this announcement further validates the company’s technology and position in the marketplace.  “While it has been rewarding to be a part of the progression of the company from start up to sale, perhaps the biggest satisfaction is our positive contribution to the impact of healthcare delivery,” said Invenshure’s Co-CEO, Troy Kopischke.  “We are excited for the entire GeneMatters team and look forward with great anticipation to the power of the Genome Medical-GeneMatters combination and the continued transformation of genetic healthcare.”

With the strategic addition of GeneMatters, Genome Medical will expand its clinical capacity and expertise across key clinical areas. Two prominent virtual genetics companies are being brought together, led by industry innovators who offer unmatched knowledge. Both companies share a similar mission and have a relentless dedication to providing the best patient care, customer solutions and service.

Recommended AI News: Connected2Fiber Launches Industry’s First Fully Automated Bid Management Capability

“It has been a great journey partnering with Invenshure to build GeneMatters, with a mission to increase access to genetic counseling and to support patient decision-making,” said Jill Davies, Co-founder and President of GeneMatters. “We are thrilled to be joining forces with Genome Medical, a leader in the delivery of genomic medicine, who shares our mission, vision and passion for patient care.”

GeneMatters will operate as a wholly owned subsidiary of Genome Medical Holding Company, with a focus on expanding the delivery of genetic services to community health systems and other partners. It will operate under the GeneMatters name and provide exceptional service to its customers.

The Series C financing was led by Casdin Capital, a committed and leading long-term investor in life sciences and genomics. New investors GV (formerly Google Ventures) and Amgen Ventures participated in this round alongside Genome Medical’s existing investors, including Perceptive Advisors, LRVHealth, Echo Health Ventures, Kaiser Permanente Ventures, Canaan Partners, Illumina Ventures, Revelation Partners, HealthInvest Equity Partners, Avestria Ventures, Flywheel Ventures, Dreamers Fund and Blue Ivy Ventures.

Recommended AI News: Qumu Announces CFO Transition Plan